IN VITRO INDUCTION OF T-LYMPHOCYTE-MEDIATED CYTOTOXICITY BY INFECTIOUS MURINE TYPE C ONCORNAVIRUSES

BY TADAYOSHI TANIYAMA AND HOWARD T. HOLDEN

From the Laboratory of Immunodiagnosis, National Cancer Institute, Bethesda, Maryland 20205

Cell-mediated immune responses have been shown to play an important role in the rejection of tumors and in tumor immunity (see reference 1 for review). Among the immune responses to a tumor graft, cytolytic T lymphocytes capable of destroying target cells carrying the relevant tumor-associated antigens have been demonstrated in experimental animals. In the Moloney murine sarcoma virus (M-MSV)\(^1\) system that has been extensively studied, M-MSV-induced tumors have been shown to have common antigens related to those induced by some murine leukemia viruses (MuLV) (2–5). Although cell-mediated immune responses induced by M-MSV have been extensively studied by many different techniques, such as the microcytotoxicity test, \(^{51}\)Cr-release cytotoxicity assay and migration inhibitory factor (MIF) assay, there have been no conclusive indications about the antigens recognized by immune T lymphocytes (see reference 6 for review).

Recently, some studies with lymphocytes from M-MSV-immune mice have suggested that the recognition of type C virion proteins appears to account for at least a part of the immune reactivity. Enjuanes et al. (7) demonstrated that the type-specific envelope antigen, gp70, of Moloney murine leukemia virus (M-MuLV) could stimulate lymphoproliferative responses by M-MSV-immune lymphocytes and could specifically inhibit cell-mediated cytotoxicity. A study in our laboratory has indicated that gp70, p12, and p30 of M-MuLV could also stimulate M-MSV-immune lymphocytes to produce MIF.\(^2\)

Initially, Plata et al. (8) and subsequently we (9, 10) reported that a secondary cytotoxic response could be induced in vitro by incubating spleen cells from M-MSV immune animals with intact tumor cells. More recently, we also demonstrated that macrophages functioned as accessory cells for the generation of a secondary cytotoxic response even when intact tumor cells were used as an antigen (10). This has led to a modified procedure for generating a secondary cytotoxic response, which facilitates

---

\( ^1 \)Abbreviations used in this paper: DMEM, Dulbecco's modified Eagle's minimal essential medium; FCS, fetal calf serum; FEF, feline embryo fibroblast; FeLV, feline leukemia virus; FIU, focus-inducing units; F-MuLV, Friend murine leukemia virus; ISC, immune spleen cells; MEF, mouse embryo fibroblast; MIF, migration inhibitory factor; M-MSV, Moloney strain of murine sarcoma virus; M-MuLV, Moloney murine leukemia virus; MuLV, murine leukemia virus(s); NSC, normal spleen cells; R-MuLV, Rauscher murine leukemia virus.

\( ^2 \)Ng, A.-K., R. S. Ames, Jr., R. K. McIntire, and R. B. Herberman. 1979. In vitro studies of cell-mediated immunity to Moloney leukemia virus and Moloney leukemia-associated antigens. Cancer Res. In press.
MURINE LEUKEMIA VIRUS-INDUCED CYTOTOXICITY

1368

Characteristics of the Tumors and Cell Lines Used in 51Chromium-release Assay

| Cells          | Strain of origin | H-2 haplotype | Inducing agent                        | Condition | Reference |
|---------------|------------------|---------------|---------------------------------------|-----------|-----------|
| MBL-2         | B6               | b             | Moloney-MuLV (M-MuLV)-induced lymphoma | TC*       | 3         |
| RBL-5         | B6               | b             | Rauscher-MuLV (R-MuLV)-induced lymphoma | TC        | 3         |
| EL-4(G-       | B6               | b             | Benzo[a]pyrene-induced lymphoma GCSA- | TC         | 3         |
| EL-4(G+)      | B6               | b             | Benzo[a]pyrene-induced lymphoma GCSA+ | TC         | 3         |
| EdG2          | B6               | b             | Gross-MuLV-induced lymphoma GCSA+     | Spleno    | 3         |
| B6-MEF        | B6               | b             | Uninfected normal mouse embryo fibroblast | TC    | 7         |
| B6-MEF-M-MuLV | B6               | b             | M-MuLV-infected B6-MEF                | TC        | 7         |
| B6-MEF-F-MuLV | B6               | b             | Friend-MuLV (F-MuLV)-infected B6-MEF  | TC        | 7         |
| B6-MEF-M-MSV  | B6               | b             | M-MSV-infected B6-MEF                 | TC        | 7         |
| B6-MEF-B-tropic | B6           | b             | B-tropic MuLV-infected B6-MEF        | TC        | 7         |
| LSTRA         | BALB/c           | d             | M-MuLV-induced lymphoma               | TC        | 3         |
| RL31          | BALB/c           | d             | Radiation-induced leukemia            | TC        | 3         |
| YAC-1         | A                | a             | M-MuLV-induced lymphoma               | TC        | 3         |
| RDM-4         | AKR              | k             | Spontaneous lymphoma                  | TC        | 11        |

* Tissue culture.

In the examination of the specificity of M-MSV-immune cytolytic T lymphocytes. In the present report, we describe our finding that infectious type C virus can induce a secondary cytotoxic response, and explore the possibility that this technique can further be used to elucidate the specificity of cytotoxic T lymphocytes.

Materials and Methods

**Mice.** C57BL/6N (B6) mice were obtained from the Rodent and Rabbit Production Section, Division of Research Services, National Institutes of Health, Bethesda, Md.

**Tumors.** Primary tumors were induced by the M-MSV (>10⁴ focus-forming units) in B6 mice as described previously (2). Usually, the tumors arose 6–7 after inoculation, reached maximum size on days 11–14, and regressed by days 22–25. For studies of the secondary cytotoxic response, spleen cells were obtained from mice 30–50 d after inoculation with M-MSV.

**Target Cells.** The characteristics and origins of the cell lines employed in this study are given in Table I (3, 7, 11). They were grown as stationary suspension or monolayer cultures in RPMI-1640 medium (Grand Island Biological Co., Grand Island, N.Y.) containing 10% fetal calf serum (FCS), 100 μg/ml streptomycin, 100 U/ml penicillin, and 50 μg/ml gentamicin (hereafter referred to as RPMI-1640-10% FCS) (12). The in vivo passaged tumor lines were maintained by serial passage in normal histocompatible recipients. The respective cell lines were assayed for the expression of viral antigens by competition radioimmunoassay (7).

**Viruses.** M-MSV was prepared from a stock originally obtained from Dr. J. B. Moloney, National Cancer Institute (NCI), Bethesda, Md., and maintained in our laboratory (2). Moloney MuLV clone IC (M-MuLV clone IC) from NIH/3T3 cells, Rauscher MuLV (R-MuLV) from JLS-V9 cells, Gross-MuLV and BALB virus-1 from NIH/3T3 cells, AKR-MuLV from AKR mouse embryo fibroblasts (originally obtained from Dr. W. P. Rowe, National Institute of Allergy and Infectious Diseases [NIAID], Bethesda, Md.), BALB virus-2 from human A673 cells, feline leukemia virus (FeLV), and baboon type C virus were obtained from the Viral Oncology Program of the National Cancer Institute through the courtesy of Dr. J. Gruber. These viruses, except for M-MSV, were purified by double sucrose density gradient ultracentrifugation and stored at –70°C until use. Ecotropic M-MuLV clone H, originally isolated by Dr. Janet Hartley, NIAID, Bethesda, Md. (13), and a variant (duatropic) of M-MuLV clone 83 (13), both propagated on 3T3FL cells in McCoy 5A medium containing 10% FCS, were obtained from Dr. Alan Rein, NCI, Bethesda, Md. A nondefective dualtropic virus (HIX virus) from M-MuLV clone IC was propagated on feline embryo fibroblast (FEF) (HIX-FEF) or human RD cells (HIX-RD) and was obtained from P. J. Fischinger, NCI, Bethesda,
Table II
Characterization of Viruses Used in the Present Study

| Virus                        | Cell line      | Tropism         | Virus particles/ml* | FIU/ml | Condition used |
|------------------------------|----------------|-----------------|---------------------|--------|----------------|
| M-MuLV clone IC              | NIH/3T3§       | NB              | 1.5 x 10^11         | 1 x 10^8 | Purified±     |
| M-MuLV clone H               | 3T3FL¶         | NB              | N.D.                | 2 x 10^9 | Supernate**   |
| M-MuLV clone 83              | 3T3FL¶         | Dualtropic      | N.D.                | 4 x 10^7 | Supernate     |
| HIX-FF                       | FEF‡           | Dualtropic      | N.D.                | 5 x 10^6 | Supernate     |
| HIX-RD                       | RD human cells¶| Dualtropic      | N.D.                | 5 x 10^6 | Supernate     |
| R-MuLV                       | JLS-V99§       | NB              | 1 x 10^11           | 3 x 10^7 | Purified      |
| Gross-MuLV passage A         | NIH/3T3§       | N               | 2.5 x 10^10         | 1 x 10^8 | Purified      |
| AKR-MuLV                     | AKR MEF§       | N               | 2.2 x 10^10         | 5 x 10^2 | Purified      |
| BALB virus-1 BC196           | NIH/3T3§       | N               | 1.2 x 10^11         | 4 x 10^7 | Purified      |
| BALB B-tropic                | SC-18¶         | B               | ND                  | 3 x 10^6 | Supernate     |
| WNI802B                      |                |                 |                     |        |               |
| BALB virus-2 BC177           | A673 human cells¶ | Xenotropic  | 1.3 x 10^11         | 7 x 10^4 | Purified      |
| Feline LV Theilen            | FL-74¶         | B               | 3.5 x 10^11         | 4 x 10^6 | Purified      |
| Baboon type C M7             | A207 human cells¶ |         | 2.0 x 10^10         | 3 x 10^6 | Purified      |

* Determined by electron microscopy.
† Focus-inducing units per milliliter in S+L— FG-10 assay, S+L— mink cell or S+L— cat 81 cell assay.
‡ Obtained from Dr. J. Gruber, National Cancer Institute, Bethesda.
¶ Obtained from Dr. A. Rein, National Cancer Institute, Bethesda.
** 24-hour supernate from the relevant confluent culture.
†† Obtained from Dr. P. Fischinger, National Cancer Institute, Bethesda.
§§ Obtained from Dr. R. Baslin, National Cancer Institute, Bethesda.

Md. (14). BALB B-tropic virus (WN 1802B), originally isolated by Dr. Janet Hartley, was propagated on SC-1 cells in McCoy’s 5A medium containing 10% FCS and was obtained from Dr. Robert H. Basin, NCI, Bethesda, Md. (15). The characteristics of the virus used in the present study are given in Table II.

Irradiation of Virus with Ultraviolet (UV)-light. Irradiation of infectious virus with UV-light (General Electric Co., Lamp Parts & Equipment Sales Operation, Cleveland, Ohio) was performed as described previously (16). In brief, virus was diluted in 1 ml of phosphate-buffered saline, placed onto a watch glass, and then irradiated with UV-light at 60 ergs/mm² per s. Treatment for 40 s (total 2,400 ergs/mm²) was shown to inactivate 1 log of infectious virus, as determined by XC syncytial plaque assay (16) and the S+L— focus assay on FG-10 (17).

Virus Infectivity Assay. Ectotropic and dualtropic M-MuLVs were assayed according to the method of Bassinet al. (17), using the S+L— focus assay on FG-10 cells (kindly provided by Dr. R. Bassin, NCI) that had been pretreated with 20 µg/ml DEAE-dextran. Assays for xenotropic virus, FeLV, and baboon type C virus were done by the focus assay in the S+L— mink cells (18) (kindly given by Dr. J. Hartley, NIAID) or the S+L— cat cell 81 (19) (obtained from Dr. P. Fischinger, NCI) in the presence of polybrene (2 µg/ml). The results of the S+L— assay are given as focus-inducing units (FIU) per milliliter. M-MSV was titrated on ST3FL (given by Dr. A. Rein, NCI) in the presence of an optimal concentration of helper virus, by the method of Bassinet al. (20), with the titer being expressed as focus-forming units per milliliter.

In Vitro Generation of a Secondary Cytotoxic Response. Spleens were removed aseptically from M-MSV-immune or normal animals and minced. The resulting single cell suspension was passed through sterile gauze and suspended in Dulbecco’s modified essential medium (DMEM) containing 10% FCS (lot RG1808, Reheis Chemical Co., Chicago, Ill.) 50 µM 2-mercaptoethanol, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 34 µg/ml L-asparagine, 116 µg/ml arginine-HCl, and 10 µg/ml folic acid (hereafter referred to as complete DMEM). Secondary cell-mediated cytotoxicity was generated in vitro using a modification of the method described by Plata et al. (8). Briefly, unseparated immune spleen cells (ISC), suspended in complete DMEM, were adjusted to a final concentration of 5 x 10⁶ cells/ml. Tumor cells to be used as stimulators were treated with 100 µg/ml mitomycin C/10⁶ cells/ml. Tumor cells were trypsinized and washed three times with RPMI-1640-10% FCS. For culture, 5 x 10⁶ immune spleen cells were mixed with different
concentrations of purified virus, tissue culture supernates containing infectious virus or \(2 \times 10^5\) mitomycin C-treated tumor cells in 2.0 ml of complete DMEM and dispensed in multiwell dishes (FB-16-24-TC, Linbro Chemicals, Hamden, Conn.). In a preliminary experiment, we found that with intact tumor cells as in the stimulus, the optimal responding cell to stimulator cell ratios were 25:1 and 20:1. Each group consisted of at least four cultures. Cultures were incubated at 37°C in a humidified atmosphere containing 5% CO\(_2\) in air. After 5 d in culture, lymphocytes were harvested and used as effector cells in a 4-h \(^{51}\)Cr-release assay.

\(^{51}\)Cr-release Assay. The procedure was described previously (9, 10). Varying numbers of effector cells were mixed with \(5 \times 10^5\) \(^{51}\)Cr-labeled target cells in a final 0.2-ml vol in microtiter plates with U-shaped wells (Linbro Scientific Co.). The plates were then centrifuged at 65 g for 2 min and were incubated at 37°C for 4 h. Supernates were then harvested with the Titertek Supernatant Collecting System (Flow Laboratories, Inc., Rockville, Md.), and the percent cytotoxicity was determined as follows:

\[
\% \text{ cytotoxicity} = \frac{\text{cpm of test supernate} - \text{cpm of autologous control}}{\text{total cpm incorporated into cells}} \times 100. 
\]

\% specific cytotoxicity = \% cytotoxicity of immune spleen cells stimulated with an antigen or a supernatant-containing infectious virus - \% cytotoxicity of immune spleen cells cultured alone or with supernate from uninfected cells.

The percent cytotoxicity of immune spleen cells cultured alone (unstimulated) was 5.0 ± 4.4 (mean ± standard deviation) for 20 experiments. An autologous control, with unlabeled target cells in place of lymphocytes, was used to measure the spontaneous release. Each experimental group was tested in quadruplicate.

Elimination of T Lymphocytes. AKR anti-C3H, anti-Thyl.2, was prepared as previously described (21). To eliminate T lymphocytes, 10-20 × 10^6 effector cells were incubated with undiluted AKR anti-C3H Thy1.2 serum (0.3 ml) for 30 min at room temperature. Next, the cells were washed once with RPMI-1640 medium, resuspended in a 1:2 dilution of normal rabbit serum (Grand Island Biological Co.) (preselected for lack of toxicity against mouse lymphocytes) as a source of complement, and incubated for 45 min at 37°C. After being washed three times, the cells were then counted and used in the test.

Results

Induction of a Cytotoxic Response: Tumor Cells vs. Virus. As has been reported previously (8-10), M-MSV-immune spleen cells could be restimulated in vitro with the relevant intact tumor cells to produce a potent secondary cytotoxic response 5 d after the initiation of culture (Table III). In addition to the routine use of MBL-2 tissue culture cells as the stimulus, we decided to investigate whether supernatant fluids from cultures of MBL-2 could substitute for the intact tumor cells. As shown in Table III, the supernate from MBL-2 cultures was as good as or better than intact tumor cells for inducing a secondary response. Normal spleen cells were not stimulated to produce a cytotoxic response with either MBL-2 or culture supernates from MBL-2 cells. Furthermore, the stimulated immune cells did not react appreciably or consistently against RLd1, a target that does not contain cross-reacting antigens.

These results prompted us to investigate the possibility that a virus released from MBL-2 was responsible for the induction of this response, because the supernate from MBL-2 tissue cultures was found to contain \(>10^5\) FIU/ml of infectious ecotropic MuLV. M-MuLV clone IG was tested for its ability to induce a secondary cytotoxic response. Addition of \(3 \times 10^5\) virus particles per culture stimulated high levels of cytotoxicity in spleen cells from animals 30 d after MSV inoculation. As with the supernate from MBL-2, no cytotoxic reactivity was seen when normal spleen cells were used as the responders.
Kinetics of the Generation of Cytolytic T Lymphocytes by M-MuLV. To investigate the time course of the secondary cytotoxic response induced by M-MuLV clone IC, multiple cultures of M-MSV immune spleen cells were stimulated with either M-MuLV clone IC or MBL-2. At different times after initiation of culture, the responding cells were harvested and tested for their cytolytic activity against MBL-2. As shown in Table IV, significant cytotoxicity was induced by M-MuLV clone IC by day 4, and by day 5 had reached a peak. Thereafter, the cytotoxicity induced by M-MuLV clone IC decreased. These kinetics were comparable to those observed in cultures containing mitomycin C-treated MBL-2 as the stimulus.

Nature of the Effector Cells. Although it has been established that T lymphocytes are the effector cells generated when intact tumor cells are used as the stimulus (8-10), it was important to determine whether the effector cells generated in a secondary cytotoxic response by M-MuLV clone IC were also T lymphocytes. To test this, M-MSV-immune spleen cells obtained after 5 d of culture with M-MuLV clone IC were treated with anti-Thyl.2 plus complement before assaying their cytolytic activity on MBL-2. As shown in Table V, treatment with anti-Thyl.2 plus complement, but not complement alone, completely abolished the cytolytic activity, indicating that the effector cells generated in the secondary cytotoxic response by M-MuLV were T lymphocytes. Similar results were obtained when tissue culture supernate from MBL-2 was used as the stimulus (data not shown).

Specificity of Cytolytic T Lymphocytes Generated by Intact MBL-2 or M-MuLV Clone IC. To determine the specificity of the cytolytic T lymphocytes, a wide panel of target cells was employed in a 4-h \(^{51}\)Cr-release assay. As shown in Table VI, cytolytic T lymphocytes generated by M-MuLV clone IC were capable of lysing MBL-2, RBL-
Table IV

| Day of culture | E/T ratio | Percent specific cytotoxicity (± SE)* |
|---------------|-----------|-------------------------------------|
|               |           | M-MuLV clone IC (3 × 10^5 VP/well) | MBL-2 (2 × 10^6 cells/well) |
| 4             | 100:1     | 28.5 (0.5)                          | 24.9 (0.6) |
|               | 30:1      | 24.6 (0.7)                          | 22.0 (0.5) |
|               | 10:1      | 19.1 (0.7)                          | 16.6 (0.8) |
| 5             | 100:1     | 39.5 (0.6)                          | 34.2 (0.7) |
|               | 30:1      | 32.4 (0.5)                          | 30.6 (0.8) |
|               | 10:1      | 30.3 (0.3)                          | 26.0 (0.6) |
| 6             | 100:1     | 22.9 (0.8)                          | 21.1 (0.7) |
|               | 30:1      | 20.5 (0.6)                          | 18.7 (0.6) |
|               | 10:1      | 16.9 (0.5)                          | 17.3 (0.8) |

* MBL-2 cells were used as the target.
‡ Virus particles per culture.

5, and EL-4(G+) targets very efficiently. In contrast, the same effector cells failed to lyse significantly RDM-4, E3G2, RL51, LSTRA, EL-4(G-), or YAC target cells. Similar patterns were obtained when MBL-2 culture supernate or MBL-2 tumor cells were employed as the stimulus. Hence, these results indicate that the antigen(s) being recognized by cytolytic T lymphocytes is associated with M-MuLV, but unrelated to Gross cell surface antigen (GCSA), because E3G2, a syngeneic Gross-MuLV-induced lymphoma, was not lysed, and RBL-5 contains Moloney antigens (gp70 and p12) on their cell surface as determined by competition radioimmunoassay (J. N. Ihle. Personal communication.). Furthermore, the above results were confirmed by using B6-MEF infected with a variety of murine type C RNA viruses, which were regularly checked for viral contamination or activation and expression of endogenous type C viruses. The results shown in Table VI clearly indicate that no cytotoxicity was detected in the uninfected or F-MuLV- or B-tropic MuLV-infected B6-MEFs by cytolytic T lymphocytes generated by M-MuLV clone IC or intact MBL-2 cells. The same effector cells, on the other hand, lysed efficiently M-MSV- or M-MuLV-infected B6-MEF, thus indicating that antigenic determinants which are recognized by cytolytic T lymphocytes, are immunologically specific for the serotype of M-MuLV.

Consistent with previous reports (8, 9, 22, 23), the cytotoxicity observed in the present study was H-2 restricted, because YAC and LSTRA, M-MuLV-induced lymphomas of A and BALB/c mice were not lysed in a 4 h ^51Cr-release assay (Table VI). Moreover, the fact that good targets (YAC and RL51) for NK activity (24) were also not killed significantly by cytolytic T lymphocytes shows that the effector cells were immune T lymphocytes but not NK cells. This result was further confirmed by a cold target inhibition study in which experiments were performed using labeled MBL-2 target cells and unlabeled competitive inhibitor cells including MBL-2 and YAC. Only MBL-2 inhibitor cells abrogated the cytolyis of MBL-2 in a dose-dependent manner whereas YAC did not inhibit (data not shown).

The Role of the Infectivity of M-MuLV in Induction of a Secondary Cytotoxic Response. In the above experiments, infectious M-MuLV clone IC was shown to induce a secondary cytotoxic response. It was important to determine if infectivity was required for induction of the response, because previous reports with other nononcogenic viruses
TABLE V
Effect of Anti-Thy 1.2 Plus Complement on Effector Cells Induced by Culture of 
M-MSV-immune Spleen Cells with M-MuLV

| Treatment         | Percent recovery of viable cells | Percent specific cytotoxicity (± SE)* |
|-------------------|----------------------------------|-------------------------------------|
| Medium            | 100                              | 36.3 (1.5)                          |
| C                 | 90                               | 32.9 (1.6)                          |
| Anti-Thy1.2 + C   | 35                               | 0 (0.7)                             |

* Effector to target cell ratio of 60:1, against MBL-2 target cells.

TABLE VI
Specificity of Cytolytic Activity of T Lymphocytes Generated in Response to M-MuLV

| Target cells | H-2 haplotype | Percent specific cytotoxicity* |
|--------------|---------------|-------------------------------|
| MBL-2        | b             | 37.5-60.9§ 47.4 21.3          |
| RBL-5        | b             | 41.3§ 22.1 18.5               |
| EL-4(G+)     | b             | 34.2§ — 1.4-8.8              |
| EL-4(G-)     | b             | -1.2-1.0§ — —                |
| E2G2         | b             | 1.7§ — —                    |
| YAC          | a             | 2.9-3.9§ 1.9 2.4-6.4         |
| RLd1         | d             | 0.8§ 1.5 4.2                |
| LSTRA        | d             | 0.8§ 1.5 4.2                |
| RDM-4        | k             | 2.6§ — 3.3                 |
| B6-MEF       | b             | 0.2-2.1¶ — 0.1-3.5          |
| B6-MEF-M-MuLV| b             | 20.5-25.5¶ — 14.2-16.8      |
| B6-MEF-M-MSV | b             | 20.8-28.9¶ — 21.6           |
| B6-MEF-F-MuLV| b             | 2.9-4.2¶ — 2.9              |
| B6-MEF-B-tropic | b          | -0.2-3.7¶ — 0.2-0.6         |

* Two values indicate the range of cytotoxicity from multiple tests; one value is percent specific cytotoxicity from one experiment.
† Antibody used as stimuli in secondary responses.
§ E/T ratios of 30:1-50:1.
¶ E/T ratios of 50:1-150:1.

were conflicting. Ertl et al. (25) reported a requirement for infectious vaccinia virus to induce virus-specific cytotoxic T lymphocytes in vivo. However, inactivated influenza virus (26) and Sendai virus (27, 28) were able to induce cytotoxic responses in vitro. Experiments were therefore performed to investigate whether inactivated M-MuLV was able to induce a secondary cytotoxic response against MBL-2. The results shown in Fig. 1A indicated that when the infectious virus was exposed to UV-light for a period resulting in a decrease to 1/1,000 of the original infectivity, 1,000-fold more virus particles were required to induce the same degree of the cytotoxicity. We considered the possibility that this treatment somehow rendered the infectious virus immunologically inactive (e.g., by conformational change of the antigens). Therefore, various doses of UV-irradiation were tested and the results are shown in Fig. 1B. Treatment of the infectious M-MuLV for 40 s (2,400 ergs/mm²) or 1 min 20 s (4,800 ergs/mm²), which decreased infectivity by 1 or 2 logs, respectively, decreased the
ability of the virus to induce a secondary cytotoxic response by ~12- to 50-fold and 100- to 300-fold, as compared to the untreated virus control. Taken together, these results suggest that there is a close correlation between the infectivity of M-MuLV and the ability to induce a secondary cytotoxic response in this system.

**Specificity of a Secondary Cytotoxic Response in the Induction Phase.** Having examined the specificity of the cytolytic T lymphocytes induced by M-MuLV clone IC, it was of interest to determine whether other murine leukemia viruses, such as ecotropic and xenotropic virus, and nonmurine type C viruses, such as FeLV and baboon type C viruses, could also induce a secondary cytotoxic response of M-MSV-immune spleen cells. The results of experiments with an exogenous ecotropic type C virus (R-MuLV) and three endogenous N-tropic and one B-tropic type C viruses are shown in Tables VII and VIII. AKR-MuLV, Gross-MuLV, BALB virus-1, and B-tropic virus were unable to induce a secondary cytotoxic response by M-MSV-immune spleen cells, even when the number of virus particles per culture was varied from $10^5$ up to $10^9$. M-MuLV clone IC, on the other hand, was consistently capable of inducing high levels of reactivity. Furthermore, no cytotoxic response was detectable against EcG2, a Gross-MuLV-induced lymphoma, in the cultures of M-MSV-immune spleen cells and Gross-MuLV or M-MuLV (data not shown). However, when M-MSV-immune spleen cells were cultured with R-MuLV (Table VII), low but significant levels of cytotoxicity were detectable.

Recently, some variants of M-MuLV, which were shown to be recombinants in the env gene region between ecotropic M-MuLV and a xenotropic virus, have been isolated (13, 14). It was of interest to determine whether these variants of M-MuLV (M-MuLV clone 83, HIX-FEF, or HIX-RD) as well as ecotropic M-MuLVs clone IC and clone H could induce a secondary cytotoxic response by M-MSV-immune spleen cells. The results shown in Table IX indicate that two ecotropic M-MuLVs consistently showed an ability to induce a secondary cytotoxic response. However, M-MuLV

---

**Fig. 1.** Effect of UV irradiation on the ability of M-MuLV clone IC to induce a secondary cytotoxic response. The infectious M-MuLV was irradiated with UV-light at 7,200 ergs/mm$^2$ (2 min, ▲) (Fig. 1A), which has been shown to decrease infectivity by 3 logs, or at 2,400 (40 s, ■) or 4,800 (1 min 20 s, ▼) ergs/mm$^2$ (Fig. 1B), which have been shown to decrease infectivity to 1 or 2 logs, respectively. The ability of UV-treated M-MuLV to induce a secondary cytotoxic response was compared to that of untreated virus (▲), MBL-2 cells were used as the target, with an effector to target cell ratio of 100:1. Note that the ability of M-MuLV to induce a secondary cytotoxic response decreased in parallel with the infectivity of M-MuLV.
Table VII

Ability of Ecotropic Viruses To Induce a Secondary Cytotoxic Response by M-MSV-immune Spleen Cells

| Exp. | Virus† | Number of virus particles |
|------|--------|--------------------------|
|      |        | $10^5$ | $10^6$ | $10^7$ | $10^8$ | $10^9$ |
| Exp. 1 | M-MuLV clone IC (3 ×)§ | 2.4 (0.4) | 6.4 (0.5) | 4.7 (0.8) | 18.3 (0.5) | 36.8 (0.5) | 18.3 (0.5) |
|      | R-MuLV | —      | 2.2 (0.8) | 2.6 (0.7) | 3.8 (0.5) | 6.9 (0.4) | 5.0 (0.5) |
|      | AKR-MuLV (4 ×) | 0.1 (0.5) | 0.7 (0.5) | 0.3 (0.7) | 1.0 (0.4) | 0 (0.7) | — |
| Exp. 2 | M-MuLV clone IC (3 ×) | 0.1 (0.9) | 0.7 (0.5) | 1.7 (1.0) | 23.1 (1.0) | 55.8 (1.6) | — |
|      | Gross-MuLV (3 ×) | 0.8 (0.0) | 1.9 (0.7) | 4.3 (0.8) | 3.3 (0.9) | 0 (0.7) | — |
| Exp. 3 | M-MuLV clone IC (1.5 ×) | — | 2.0 (0.5) | 6.3 (0.8) | 16.8 (0.6) | 28.4 (0.6) | — |
|      | BALB-virus-1 (1.5 ×) | — | 0.1 (0.7) | 1.0 (0.5) | 0 (0.5) | 0.2 (0.5) | — |

* MBL-2 cells were used as a target. E:T ratio was 80:1 in Exp. 1, 100:1 in Exp. 2 and 80:1 in Exp. 3.
† Purified by double sucrose density gradient.
§ Number of virus particles per culture is the number in parentheses times the heading of each column.
¶ Not done.

clone 83, HIX-FEF, and HIX-RD were found to be inactive, suggesting that the env gene product, gp70, was important in this response.

Aoki et al. (29) had reported that SIRC cells infected with some xenotropic viruses inhibited the cytolyis by anti-M-MSV cytolytic T lymphocytes. Therefore, an experiment employing xenotropic BALB virus-2 was performed. As shown in Table X, BALB virus-2 was inactive, whereas M-MuLV clone IC was able to induce a secondary cytotoxic response in the same experiment. We also evaluated whether type C viruses derived from other species could generate a secondary cytotoxic response by M-MSV-immune spleen cells. The results shown in Table XI clearly indicate that FeLV and baboon type C viruses were inactive. Taken together, these results strongly suggest that the induction of a secondary cytotoxic response by M-MSV-immune spleen cells was immunologically type specific for M-MuLV.

Discussion

Results obtained in the present study indicate that M-MuLV can induce a strong secondary cytotoxic response by M-MSV-immune spleen cells. The specificity of the response induced by M-MuLV was the same as that induced by the primary response and the effector cells were shown to be T lymphocytes. Although the supernate of tumor cells (MBL-2 in these experiments) stimulated a cytotoxic response as strong as that induced by the tumor cells themselves, it is not clear what proportion of the response induced by the intact cells can be accounted for by the production of virus. First, the concentration of MBL-2 tumor cells that we used to generate the supernate was 5- to 10-fold higher than the concentration employed in the secondary response culture and, therefore, the increase in cell concentration could have yielded higher titers of virus in the supernate than are normally produced in the secondary response cultures. In addition, we have recently found that infectious virus is most effective at inducing a secondary response when added during the first 24 h of culture (T. Taniyama. Unpublished observations.). Therefore, it would be important to have high concentrations of virus during the early phase of the in vitro secondary response and further testing would have to be performed to determine whether the rate of virus production by the tumor cells was sufficient to meet these requirements. Second, although LSTRA induces a potent secondary cytotoxic response in syngeneic BALB/
MURINE LEUKEMIA VIRUS-INDUCED CYTOTOXICITY

Table VIII

| Virus | Dose (FIU/well) | Percent specific cytotoxicity (± SE) vs. MBL-2 |
|-------|----------------|---------------------------------------------|
|       |                | 100:1* | 30:1 | 10:1 |
| M-MuLV clone IC | 4 x 10⁶ | 45.4 (2.1) | 40.8 (1.6) | 39.4 (1.1) |
| M-MuLV clone IC | 4 x 10⁵ | 38.5 (1.3) | 36.3 (1.4) | 33.5 (1.8) |
| M-MuLV clone IC | 4 x 10⁴ | 25.0 (1.3) | 17.2 (0.6) | 10.6 (1.2) |
| B-tropic virus | 4 x 10⁶ | 1.0 (0.7) | 0.6 (0.3) | -1.2 (0.4) |
| B-tropic virus | 2 x 10⁶ | -1.2 (0.3) | -1.2 (0.8) | 0.3 (1.2) |
| B-tropic virus | 1 x 10⁵ | -1.4 (0.4) | 0.8 (1.2) | -1.9 (0.7) |
| Supernatant-MBL-2 | 8 x 10⁵ | 32.6 (1.5) | 16.7 (0.2) | 12.4 (0.3) |
| Supernatant-MBL-2 | 4 x 10⁵ | 27.3 (1.2) | 14.4 (0.7) | 9.6 (0.9) |

* Effector to target cell ratio.
‡ Specific cytotoxicity was calculated by subtracting percent cytotoxicity of immune cells cultured alone from percent cytotoxicity of immune cells cultured with virus or supernate.
§ Specific cytotoxicity was calculated by subtracting percent cytotoxicity of immune cells cultured with control-uninfected supernate from the relevant cell line from percent cytotoxicity of immune cells cultured with the supernate containing the infectious virus.

The results in the present study also suggest that for virus to be able to induce a secondary cytotoxic response, it must be infectious. When M-MuLV was irradiated with UV-light at doses which caused a decrease in infectivity of either 1, 2, or 3 logs as determined by the XC-plaque assay, the ability of irradiated M-MuLV to induce a secondary cytotoxic response decreased in parallel to the infectivity. Although this result suggests that there was an association between infectivity of the virus and its ability to induce a secondary cytotoxic response, at least two other possible mechanisms for this can be considered. The first is that the UV irradiation rendered the virus immunologically inactive. Although this is certainly possible, it is not likely because it has been shown that UV irradiation mainly affects RNA species and not proteins (30). The second alternative is that infection with, and replication of, M-MuLV, and not just adsorption of virus, was required for the formation of immunologically active antigens on the cell surface. Although low doses of infectious M-MuLV could induce detectable cytolytic T lymphocytes, little cytotoxicity was generated in the presence of 10⁵- to 10⁶-fold higher concentrations of virus that had
Table IX

Ability of Ecotropic M-MuLVs and Variants (Dualtropic) of M-MuLV Clone IC To Induce a Secondary Cytotoxic Response

| Virus                | Dose (FIU/well) | Percent specific cytotoxicity (± SE) vs. MBL-2 |
|----------------------|-----------------|---------------------------------------------|
|                      |                 | 100:1* | 70:1   | 10:1   |
| M-MuLV clone IC      | $4 \times 10^6$ | 52.1 (0.8) | 50.0 (1.9) | 34.5 (1.4) |
| M-MuLV clone IC      | $4 \times 10^5$ | 42.3 (1.4) | 40.8 (1.0) | 27.8 (0.5) |
| M-MuLV clone IC      | $4 \times 10^4$ | 13.2 (0.6) | 11.8 (0.5) | 8.8 (0.9) |
| M-MuLV clone H       | $2 \times 10^6$ | 30.1 (0.5)§ | 27.7 (0.6) | 21.5 (0.6) |
| M-MuLV clone H       | $4 \times 10^5$ | 21.6 (0.3) | 17.6 (0.4) | 15.1 (0.4) |
| HIX-FEF              | $5 \times 10^5$ | 2.2 (0.3)§ | 2.9 (0.5) | 2.4 (0.8) |
| HIX-FEF              | $1 \times 10^5$ | 2.5 (0.8) | 1.5 (0.7) | 1.8 (0.6) |
| HIX-RD               | $5 \times 10^3$ | 1.2 (0.4)§ | 1.0 (0.1) | 0.9 (0.6) |
| HIX-RD               | $1 \times 10^3$ | 2.0 (0.6) | 2.1 (0.9) | 1.2 (1.0) |
| M-MuLV clone 83      | $4 \times 10^5$ | 1.5 (1.0)§ | 2.1 (0.8) | 1.5 (0.6) |
| M-MuLV clone 83      | $8 \times 10^4$ | -1.2 (0.8) | 1.3 (0.6) | 2.1 (0.8) |

* As in Table VIII.
‡ As in Table VIII.
§ As in Table VIII.

been UV-irradiated to reduce the titer by 7 logs (data not shown). In recent experiments using purified M-MuLV gp70 (5 µg/ml), we have been unsuccessful in inducing a secondary cytotoxic response (unpublished data), although it may be possible to induce a response with much higher concentrations of M-MuLV gp70. Therefore, infectivity of virus appears to be necessary for the induction of a secondary cytotoxic response. Our results should be compared to those by Braciale and Yap (26) and others (27, 31). Inactivated Sendai virus or virion proteins were shown to induce virus-specific cytotoxic responses (27, 28), and to sensitize target cells for lysis by cytolytic T lymphocytes (27, 31). Braciale and Yap also found that influenza virus inactivated by UV light was able to induce a secondary cytotoxic response but failed to sensitize target cells for lysis (26). Nevertheless, it should be noted that Sendai virus possesses a fusion protein which allows for the efficient integration of virion antigens into cell surface cytoplasmic membranes (32). Thus, the requirement for infectivity with M-MuLV suggests that absorption of the inactivated virus is not sufficient for immunogenicity. It seems likely that integration of M-MuLV into the cell membranes of responding cells or accessory cells, via infection, is needed for the formation of stimulatory antigens. These results are compatible to those of Ertl et al. (25) and Braciale and Yap (26) who showed that infectivity of viruses was required for the induction of cytolytic T lymphocytes in vivo by using vaccinia and influenza viruses. Currently, we are investigating which types of the cells are infected with M-MuLV.

In some other studies involving cytotoxic reactivity against type C viral antigens, it appears that noninfectious materials were capable of inducing an in vitro secondary cytotoxic response. Alaba and Law (33) have recently reported that spleen cells from mice immunized with antigen solubilized from the plasma membrane of a Rauscher virus-induced lymphoma could be restimulated in vitro with the same antigen to become cytotoxic. Bruce et al. (34) found that disrupted MuLV could stimulate a secondary response by spleen cells from rats immunized with a Gross virus-induced lymphoma. In contrast, we have previously tested several materials (other than...
TABLE X
Failure of a Xenotropic Virus (BALB Virus-2) To Induce a Secondary Cytotoxic Response by M-MSV-immune Spleen Cells

| Number of virus particles | E/T ratio | Percent specific cytotoxicity (± SE) vs. MBL-2 |
|---------------------------|-----------|-----------------------------------------------|
|                           |           | M-MuLV clone IC | BALB virus-2 |
|                           |           |                  |              |
| $3 \times 10^6$           | 100:1     | 0 (0.6)          | 2.0 (0.9)    |
|                           | 30:1      | 0 (0.7)          | 1.9 (0.7)    |
|                           | 10:1      | 0 (0.5)          | 0.6 (0.6)    |
| $3 \times 10^7$           | 100:1     | 13.8 (1.0)       | 1.9 (0.7)    |
|                           | 30:1      | 7.1 (0.9)        | 0.9 (0.7)    |
|                           | 10:1      | 3.9 (0.7)        | 1.9 (0.6)    |
| $3 \times 10^8$           | 100:1     | 34.7 (0.7)       | 2.2 (1.0)    |
|                           | 30:1      | 27.2 (1.3)       | 1.1 (0.9)    |
|                           | 10:1      | 17.3 (0.8)       | 2.9 (1.0)    |
| $3 \times 10^9$           | 100:1     | 41.0 (0.8)       | 0.5 (0.8)    |
|                           | 30:1      | 37.0 (1.0)       | 0 (0.5)      |
|                           | 10:1      | 25.5 (1.1)       | 2.1 (0.7)    |

infectious virus) derived from MBL-2 tumor cells (among these were subcellular extracts obtained by freezing and thawing, and fractions solubilized by NP-40, deoxycholate, and 3M KCl) for their ability to stimulate a secondary cytotoxic response by M-MSV-immune spleen cells and found them to be inactive (unpublished observations). This may have been a result of insufficient antigenicity of the solubilized material or, in light of the data discussed in this paper, to insufficient titers of infectious virus in these preparations. Alternatively, some of the different results that have been obtained in various studies may be related to the method of primary immunization; we used virus for immunization whereas Alaba and Law (33) used soluble antigen and Bruce et al. (34) employed viable tumor cells.

Although tumor immune responses in the MSV system have been extensively studied in many laboratories, there is no agreement on the nature of the antigenic specificities of the cellular response. Gomard et al. (23) examined the nature of the cell surface antigens, and found that Friend-Moloney-Rauscher-like antigens appeared to be major antigenic determinants. Herberman et al. (3) reported that the surface antigens recognized by anti-M-MSV cytolytic T lymphocytes were related to the expression of endogenous type C virus. Furthermore, Aoki et al. (29), using a cold target cell inhibition assay, reported that xenotropic virus-producing SIRC cells could inhibit the anti-M-MSV response. Gorczynski and Knight (35) found p30 to be one of the antigenic determinants. More recently, Enjuanes et al. (7) found that the primary anti-M-MSV cytotoxic response was specific for M-MuLV, and especially for its envelope gp70, as determined by $^{51}$Cr release inhibition by purified virion components. In the present study, we examined the specificity of the cytotoxic response in both the induction and effector phases. Effector cells generated by M-MuLV clone IC could lyse efficiently MBL-2, EL-4(G+), B6-MEF-M-MSV, and B6-MEF-M-MuLV, but did not significantly affect EL-4(G−), YAC, RL51, RDM-4, B6-MEF, B6-MEF-B-tropic, B6-MEF-F-MuLV, and EzG2, thus indicating that the determinant(s) recognized by cytolytic T lymphocytes was closely associated with M-MuLV but not with a variety of other murine type C oncornaviruses. These results
T. TANIYAMA AND H. T. HOLDEN

### Table XI

**Ability of M-MuLV Clone IC or Nonmurine Type C Viruses To Induce a Secondary Cytotoxic Response by M-MSV-immune Spleen Cells**

| Exp. | Virus            | E/T ratio | Number of virus particles |
|------|------------------|-----------|--------------------------|
|      |                  |           | 3 x 10⁶ | 3 x 10⁷ | 3 x 10⁸ | 3 x 10⁹ | 3 x 10¹⁰ |
| 1    | M-MuLV clone     | 80:1      | 6.2 (0.7) | 11.7 (1.0) | 31.3 (1.2) | 43.7 (1.6) | ---*     |
|      |                  | 30:1      | 4.2 (1.0) | 8.6 (1.6) | 26.3 (1.9) | 42.3 (0.5) | ---       |
|      | FeLV Theilen     | 80:1      | 0.7 (0.5) | 1.8 (0.6) | 1.3 (0.5) | 1.6 (0.6) | ---       |
|      |                  | 30:1      | 0.3 (0.7) | 0 (0.5) | 0.3 (0.5) | 0.6 (0.7) | ---       |
| 2    | M-MuLV clone     | 50:1      | 0 (0.7) | 1.5 (0.7) | 19.4 (0.6) | 32.3 (0.9) | 41.3 (1.8) |
|      |                  | 30:1      | 0 (0.4) | 0.9 (0.7) | 0.9 (0.9) | 18.3 (0.6) | 26.5 (1.3) |
|      | Baboon M7        | 50:1      | 0 (0.6) | 0 (0.3) | 0.1 (0.8) | 1.6 (0.5) | 2.1 (1.3)  |
|      | type C           | 30:1      | 0.1 (0.7) | 0.7 (0.7) | 0.1 (0.8) | 1.3 (0.4) | 1.4 (0.6)  |

* Not done.

**Percent specific cytotoxicity (± SE) vs. MBL-2**

The support the findings of Cerny and Essex (36) and Cloyd et al. (37) showing that Moloney antigens are different from Friend and Rauscher antigens as determined by immunofluorescence microscopy.

The M-MuLV-stimulated effector cells also lysed RBL-5 (induced by R-MuLV) and EL-4(G+) targets, which would appear to be against an M-MuLV-restricted specificity. However, RBL-5 cells contained a significant amount of M-MuLV antigens (gp70 and p12), as determined by competition radioimmunoassay (J. Lee, personal communication) and therefore, it is not surprising that intact RBL-5 or supernate of RBL-5 were also capable of inducing a secondary cytotoxic response (unpublished data). The present results with EL-4(G+) are compatible with previous data from our laboratory (3) indicating that these cells are susceptible to lysis by primary anti-M-MSV immune cells and can inhibit the cytolysis of RBL-5 or MBL-2 in a cold target inhibition assay. Ng et al. (38) also have shown that anti-M-MSV serum lysed EL-4(G+) in the presence of complement. EL-4(G+) cells susceptible to the lysis by the effector cells were shown to contain NB-tropic and xenotropic endogenous type C viruses (39). Thus, although EL-4(G+) expresses serologically detectable GCSA, it seems possible that EL-4(G+) contains an endogenous MuLV closely associated to M-MuLV, instead of or in addition to Gross-MuLV.

In the induction phase, only ecotropic M-MuLVs clone IC and clone H were able to induce a secondary cytotoxic response by M-MSV-immune spleen cells. In contrast, AKR-MuLV, Gross-MuLV, BALB-B-tropic virus, and BALB virus-1 failed to induce such responses, indicating that this response was not a result of these characterized endogenous murine type C viruses. However, it is still possible that a particular endogenous type C virus was responsible for the induction of this response. When R-MuLV was used as the stimulus, low but significant levels of cytotoxicity could be induced, thus indicating some cross-reactivity, perhaps of a minor antigenic determinant(s), between M- and R-MuLVs, because type-, group- and interspecies-specific determinants of gp70 and p30 have been found by radioimmunoassay (40). Thus, it appears from the above results that the induction of in vitro secondary cytotoxic responses by virus is specific for M-MuLV and related viruses.

Because some variants (M-MuLV clone 83, HIX-FEF, or HIX-RD) of M-MuLV...
clone IC have been isolated and characterized as recombinants in the env gene between an ecotropic M-MuLV and xenotropic virus (13, 14, 41), we tested for the ability of M-MuLV clone 83, HIX-FEF or HIX-RD to induce a secondary cytotoxic response by M-MSV-immune spleen cells. The two ecotropic M-MuLV clone IC and clone H were able to induce the response, whereas dualtropic M-MuLV clone 83, HIX-FEF, and HIX-RD failed to do so, indicating that type-specific determinants of M-MuLV gp70 are important in this system. It should be noted that when mouse cells were infected with M-MuLV clone 83 or HIX-FEF, infectious virus was released into the supernate, thus indicating that the lack of stimulation by M-MuLV clone 83 or HIX-FEF was not a result of an inability to infect mouse cells (data not shown).

Thus, by studying the ability of infectious viruses to induce a secondary response, we have found that both the induction and effector phases of the in vitro secondary cytotoxic response in the M-MSV system are strongly associated with the type-specific determinants of M-MuLV gp70. Furthermore, this experimental approach should facilitate the detailed analysis of the cell-mediated cytotoxic response to oncornaviruses.

### Summary

We have developed a system to induce oncornavirus-specific secondary cytotoxic response in vitro. When Moloney strain of murine sarcoma virus-immune spleen cells were cultivated with purified infectious Moloney murine leukemia virus (M-MuLV) or with supernates of tissue culture cells containing infectious virus, a virus-specific secondary cytotoxic response directed against type-specific determinant(s) of M-MuLV was generated in vitro, as determined by a 4-h $^{51}$Cr-release assay. The effector cells were susceptible to the treatment with anti-Thyl.2 plus complement, but were unrelated to natural killer cells (NK), because they could not lyse some target cells that are highly sensitive to NK activity. This response was primarily (or largely) type-specific for M-MuLV in both the induction phase and the interaction between effector cells and target cells. Furthermore, a product of the env gene of M-MuLV, perhaps gp70, appeared to be responsible for this response, because viruses with recombinations in the env gene between ecotropic M-MuLV and a xenotropic virus failed to induce a response. When infectious M-MuLV was exposed to UV-light at different doses, the ability of UV-treated M-MuLV to induce a secondary cytotoxic response decreased in parallel with infectivity, indicating that infectivity was necessary for the induction of this response.

We are grateful to Dr. Janet W. Hartley for valuable discussions and for the use of a UV-light, to Doctors J. N. Ihle, R. B. Bassin, A. Rein, P. Fischinger, and Y. Inoue for performing virus typing of cell lines and for gifts of cell lines and viruses, and to Dr. G. Shearer for giving us a tumor. We also gratefully thank Dr. R. B. Herberman for his many suggestions during this work and for his thorough review of the manuscript.

Received for publication 15 May 1979.

### References

1. Herberman, R. B. 1974. Cell-mediated immunity to tumor cells. *Adv. Cancer Res.* 19:207.
2. Lavrin, D. H., R. B. Herberman, M. Nunn, and N. Soares. 1973. In vitro cytotoxicity studies of murine sarcoma virus-induced immunity in mice. *J. Natl. Cancer Inst.* 51:1497.
3. Herberman, R. B., T. Aoki, M. Nunn, D. H. Lavrin, N. Soares, A. Gazdar, H. T. Holden, and K. S. S. Chang. 1974. Specificity of $^{51}$Cr-release cytotoxicity of lymphocytes immune to murine sarcoma virus. *J. Natl. Cancer Inst.* 53:1103.

4. Leclerc, J. C., E. Gomard, and J. P. Levy. 1972. Cell-mediated reaction against tumors induced by oncornaviruses. I. Kinetics and specificity of the immune response in murine sarcoma virus (MSV)-induced tumors and transplanted lymphomas. *Int. J. Cancer.* 10:589.

5. Lamon, E. W., H. M. Skurzak, and E. Klein. 1972. The lymphocytes response to a primary viral neoplasm (MSV) through its entire course in BALB/c mice. *Int. J. Cancer.* 10:581.

6. Levy, J. P., and J. C. Leclerc. 1976. The murine sarcoma virus-induced tumor: Exception or general model in tumor immunology? *Adv. Cancer Res.* 24:1.

7. Enjuanes, L., J. C. Lee, and J. N. Ihle. 1979. Antigenic specificities of the cellular response of C57BL/6 mice to the Moloney leukemia/sarcoma virus complex. *J. Immunol.* 122:665.

8. Plata, F., J.-C. Cerottini, and K. T. Brunner. 1975. Primary and secondary in vitro generation of cytolytic T lymphocytes in the murine sarcoma virus system. *Eur. J. Immunol.* 5:227.

9. Holden, H. T., S. Landolfo, and R. B. Herberman. 1977. T-cell dependent reactivity against tumor-associated antigens on allogeneic target cells. *Transplant. Proc.* 9:1149.

10. Taniyama, T., and H. T. Holden. 1979. Requirement of histocompatible macrophages for the induction of a secondary cytotoxic response to syngeneic tumor cells in vitro. *J. Natl. Cancer Inst.* 56:611.

11. Sachs, D. H., and J. L. Gone. 1975. Ir-associated murine alloantigens: Demonstration of multiple Ia specificities in H-2 alloantisera after selective absorptions. *J. Immunol.* 114:165.

12. Holden, H. T., R. K. Oldham, J. R. Ortealdo, and R. B. Herberman. 1977. Standardization of chromium-51 release, cell-mediated cytotoxicity assay: Cryopreservation of mouse effector and target cells. *J. Natl. Cancer Inst.* 56:611.

13. Troxler, D. H., D. Lowy, R. Howk, H. Young, and E. M. Scolnick. 1977. Friend strain of spleen focus-forming virus is a recombinant between ecotropic murine type C virus and the env gene region of xenotropic type C virus. *Proc. Natl. Acad. Sci. U. S. A.* 74:4671.

14. Fischinger, P. J., A. E. Frankel, J. H. Elder, R. A. Lerner, J. N. Ihle, and D. P. Bolognesi. 1978. Biological, immunological, and biochemical evidence that HIX virus is a recombinant between Moloney leukemia virus and a xenotropic C type virus. *Virology.* 90:241.

15. Hartley, J. W., and W. P. Rowe. 1975. Clonal cell lines from a feral mouse embryo which lack host-range restrictions for murine leukemia viruses. *Virology.* 65:128.

16. Rowe, W. P., W. E. Pugh, and J. W. Hartley. 1970. Plaque assay techniques for murine leukemia viruses. *Virology.* 42:1136.

17. Bassin, R. H., N. Tuttle, and P. J. Fischinger. 1971. Rapid cell culture assay technique for murine leukemia viruses. *Nature (Lond.)* 229:564.

18. Peebles, P. T. 1975. An in vitro focus-induction assay for xenotropic murine leukemia virus, feline leukemia virus C, and the feline-primate viruses RD-114/CCC/M-7. *Virology.* 67:288.

19. Fischinger, P. J., C. S. Blevins, and S. Nomura. 1974. Simple, quantitative assay for both xenotropic murine leukemia and ecotropic feline leukemia viruses. *J. Virol.* 14:177.

20. Bassin, R. H., N. Tuttle, and P. J. Fischinger. 1970. Isolation of murine sarcoma virus-transformed mouse cells which are negative for leukemia virus from agar suspension cultures. *Int. J. Cancer.* 5:695.

21. Herberman, R. B., M. E. Nunn, D. H. Lavrin, and R. J. Asofsky. 1973. Effect of antibody to $\theta$ antigens on cell mediated immunity induced in syngeneic mice by murine sarcoma virus. *J. Natl. Cancer Inst.* 51:1509.

22. Plata, F., V. Jongenneel, J.-C. Cerottini, and K. T. Brunner. 1976. Antigenic specificity of the cytolytic T lymphocytes (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells. *Eur. J. Immunol.* 6:823.

23. Gomard, E., J. P. Levy, F. Plata, Y. Henin, V. Duprez, A. Bismuth, and T. Reme. 1978.
Studies on the nature of the cell surface antigen reacting with cytolytic T lymphocytes in murine oncornavirus-induced tumors. *Eur. J. Immunol.* 8:228.

24. Herberman, R. B., and H. T. Holden. 1978. Natural cell-mediated immunity. *Adv. Cancer Res.* 27:305.

25. Ertl, H. C. J., R. H. W. Gerike, and U. H. Koszinowski. 1977. Virus-specific T-cell sensitization. Requirement for vaccinia virus-specific T-cell sensitization in vivo. *Immunogenetics*. 4:515.

26. Braciale, T. J., and K. L. Yap. 1978. Role of viral infectivity in the induction of influenza virus specific cytotoxic T cells. *J. Exp. Med.* 147:1236.

27. Schrader, J. W., and G. M. Edelman. 1977. Joint recognition by cytotoxic T cells of inactivated Sendai virus and products of the major histocompatibility complex. *J. Exp. Med.* 145:523.

28. Finberg, R., M. Mescher, and S. J. Burakoff. 1978. The induction of virus-specific cytotoxic T lymphocytes with solubilized viral and membrane proteins. *J. Exp. Med.* 148:1620.

29. Aoki, T., R. B. Herberman, and M. Liu. 1975. Heterogeneity of surface antigens on endogenous type C virus-producing sublines derived from a clonal line of BALB/3T3 cells. *Intervirology.* 5:31.

30. Yoshikura, H. 1972. Effect of 5-fluorouracil on ultraviolet inactivation of virus production by murine sarcoma-leukemia virus complex carrier cells. *Virology.* 48:193.

31. Sugamura, K., K. Shimizu, and F. H. Bach. 1978. Involvement of fusion activity of ultraviolet light-inactivated Sendai virus in formation of target antigens recognized by cytotoxic T cells. *J. Exp. Med.* 148:276.

32. Hosaka, Y., and K. Shimizu. 1977. Cell fusion by Sendai virus. In *The Cell Surface of Animal Development*. G. Poste and G. N. Nicolsm, editors. North Holland/American Elsevier, New York. 129.

33. Alaba, O., and L. W. Law. 1978. Secondary induction of cytotoxic T lymphocytes with solubilized syngeneic tumor cell plasma membrane. *J. Exp. Med.* 148:1435.

34. Bruce, J., N. A. Mitchison, and G. R. Shellam. 1976. Studies on a Gross-virus-induced lymphoma in the rat. III. Optimisation, specificity and applications of the in vitro immune response. *Int. J. Cancer.* 17:342.

35. Knight, R. A., and R. M. Gorczynski. 1975. Cell-mediated immunity to Moloney sarcoma virus in mice. I. Analysis of antigens responsible for lymphocyte stimulation in regressor mice. *Int. J. Cancer.* 15:48.

36. Cerny, J., and M. Essex. 1974. Membrane antigens of murine leukemia cells. *Nature (Lond).* 251:742.

37. Cloyd, M. W., D. P. Bolognesi, and D. D. Bigner. 1977. Immunofluorescent analysis of expression of the RNA tumor virus major glycoprotein, gp71, on surfaces of virus-producing murine and other mammalian species cell lines. *Cancer Res.* 37:922.

38. Ng, A.-K., K. R. McIntire, H. T. Holden, and R. B. Herberman. 1978. Serologic analysis of tumor-associated surface antigens on a Moloney leukemia virus-induced lymphoma, MBL-2. *J. Immunol.* 121:856.

39. Aoki, T., R. B. Herberman, J. W. Hartley, M. Liu, M. J. Walling, and M. Nunn. 1977. Surface antigens on transplantable tumor cell lines producing mouse type C viruses. *J. Natl. Cancer Inst.* 58:1069.

40. Strand, M., and J. T. August. 1974. Structural proteins of mammalian oncogenic RNA viruses: multiple antigenic determinants of the major internal protein and envelope glycoprotein. *J. Virol.* 13:171.

41. Shih, T. Y., M. O. Weeks, D. H. Troxler, J. M. Coffin, and E. M. Scolnick. 1978. Mapping host range-specific oligonucleotides within genomes of the ecotropic and mink cell focus-inducing strains of Moloney murine leukemia virus. *J. Virol.* 26:71.